Compare · LQDA vs PULM

LQDA vs PULM

Side-by-side comparison of Liquidia Corporation (LQDA) and Pulmatrix Inc. (PULM): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both LQDA and PULM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • LQDA is the larger of the two at $5.17B, about 1098.0x PULM ($4.7M).
  • Both names hit the wire about 9 times in the past 4 weeks.
  • LQDA has more recent analyst coverage (23 ratings vs 0 for PULM).
MetricLQDAPULM
Company
Liquidia Corporation
Pulmatrix Inc.
Price
-
-
Market cap
$5.17B
$4.7M
1M return
-
-1.47%
1Y return
-
-71.43%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2018
2014
News (4w)
9
9
Recent ratings
23
0
LQDA

Liquidia Corporation

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

PULM

Pulmatrix Inc.

Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal infections and allergic/hypersensitivity reactions to fungus in patients with severe lung diseases comprising asthma, cystic fibrosis, and allergic bronchopulmonary aspergillosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with lung cancer and chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Latest LQDA

Latest PULM